CUAMC
ITOS

China Universal Asset Management Company’s iTeos Therapeutics ITOS Stock Holding History

China Universal Asset Management Company’s Portfolio ITOS Stock Details ITOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-7,687
Closed -$76.6K – 498
2025
Q2 		$76.6K Buy
7,687
+359
+5% +$2.89K 0.01% 386
2025
Q1 		$43.7K Sell
7,328
-419
-5% -$3.08K ﹤0.01% 427
2024
Q4 		$59.5K Buy
7,747
+723
+10% +$6.21K 0.01% 441
2024
Q3 		$71.7K Buy
7,024
+2,646
+60% +$40.4K 0.01% 375
2024
Q2 		$65K Sell
4,378
-2,499
-36% -$35.8K 0.01% 336
2024
Q1 		$93.8K Buy
6,877
+2,737
+66% +$29.8K 0.01% 380
2023
Q4 		$45.3K Buy
4,140
+3,216
+348% +$31.9K 0.01% 379
2023
Q3 		$10.1K Buy
924
+455
+97% +$5.82K ﹤0.01% 345
2023
Q2 		$6.21K Sell
469
-13
-3% -$185 ﹤0.01% 350
2023
Q1 		$6.56K Buy
482
+121
+34% +$2.17K ﹤0.01% 340
2022
Q4 		$7.05K Buy
361
+28
+8% +$547 ﹤0.01% 261
2022
Q3 		$6K Buy
+333
New +$7.67K ﹤0.01% 254

Other funds holding ITOS

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

China Universal Asset Management Company's ITOS Position: Q3 2025 in Review

China Universal Asset Management Company sold out of iTeos Therapeutics (ITOS) in Q3 2025, closing a stake of 7,687 shares — an estimated $76.6K sold.

China Universal Asset Management Company first reported a position in ITOS in Q3 2022 and held it in 12 quarters. The position peaked at $93.8K in Q1 2024. 1 fund tracked by Wall St. Rank holds ITOS as of Q3 2025.

  • China Universal Asset Management Company reported no remaining iTeos Therapeutics position as of Q3 2025 after selling out during the quarter.
  • China Universal Asset Management Company sold 7,687 iTeos Therapeutics shares in Q3 2025, an estimated $76.6K.
  • China Universal Asset Management Company first reported a position in iTeos Therapeutics in Q3 2022 and held it in 12 quarters.
  • China Universal Asset Management Company's iTeos Therapeutics position peaked at $93.8K in Q1 2024.
  • 1 fund tracked by Wall St. Rank held iTeos Therapeutics as of Q3 2025.

Based on China Universal Asset Management Company's 13F filing for Q3 2025, filed 10 Nov 2025.